Questions stay concerning use of giredestrant, oral SERDs for breast most cancers
December 21, 2025
2 min watch
SAN ANTONIO — On this video, Eleonora Teplinsky, MD, discusses the lidERA trial, introduced at San Antonio Breast Most cancers Symposium, and what questions and analysis stay to be used of giredestrant in breast most cancers.
The part 3 lidERA trial in contrast giredestrant (Genentech, Roche), an oral selective estrogen receptor degrader, with standard-of-care chemotherapy amongst sufferers with early-stage, hormone receptor-positive, HER2-negative breast most cancers.
“Rather a lot will evolve within the coming months and years,” Teplinsky, head of breast and gynecologic medical oncology at Valley-Mount Sinai Complete Most cancers Care, instructed Healio. “We even have quite a few different SERD trials being carried out in early-stage breast most cancers, and I feel as we begin to get the outcomes of these research, that will even change how we method endocrine remedy for early-stage breast most cancers.”
Sources/Disclosures
Supply:
Healio Interviews
Disclosures:
Healio was unable to verify related monetary disclosures on the time of publication.
Ask a medical query and faucet into Healio AI’s information base.
- PubMed, enrolling/recruiting trials, pointers
- Scientific Steering, Healio CME, FDA information
- Healio’s unique each day information protection of medical knowledge
